Outset Medical CEO Leslie Trigg Kept Selling Small Lots Into a 2026 Margin-Rebuild Story

Leslie Trigg, the chief executive of Outset Medical (OM), kept trimming shares in small lots through January and February 2026. The sales were not huge in dollar terms, but the cadence matters because they arrived just as Outset was trying to convince investors that its operating reset was gaining traction.

Key Facts

Date	Code	Shares	Price	Shares After
2026-02-17	S	3,361	$3.35	102,342
2026-01-21	S	2,120	$5.05	105,703
2026-01-20	S	11,794	$5.12	107,823
2025-11-17	S	916	$4.60	121,412

What The Pattern Says

The filing trail does not look like an all-at-once exit. It looks more like a measured, recurring disposal pattern. Trigg still reported more than 100,000 Outset shares after the latest February sale, which is materially different from a complete walk-away.

There is also an important detail in the most recent insider feed: Trigg's March 23 reporting activity related to Exact Sciences (EXAS), where she also serves as a director. That means investors reading the feed need to separate her board-related dispositions in one company from her continuing sale pattern in Outset Medical.

Why The Company Context Matters

Outset's February 11, 2026 earnings release gave investors a more constructive operating story than the stock had reflected through much of 2025. Fourth-quarter gross margin improved to 42.4% from 36.5% a year earlier, full-year revenue rose to $119.5 million, and year-end cash reached $173 million. Management guided 2026 revenue to $125 million to $130 million with non-GAAP gross margin in the low-to-mid 40% range.

That backdrop makes Trigg's sales worth watching, but not automatically bearish. Outset is still a turnaround story in a difficult med-tech niche, with investors comparing its execution against better-established names such as Insulet (PODD), DexCom (DXCM), Abbott (ABT), Medtronic (MDT), and Baxter (BAX). The issue is not that Trigg sold a few thousand shares. The issue is whether the company can convert improved margins into a durable rerating.

What Investors Should Watch

• Whether the small-lot sale cadence continues after the February transaction.
• Whether Outset can hold the gross-margin improvement it reported with fourth-quarter 2025 results.
• Whether recurring revenue from consumables and service keeps growing fast enough to support the cash runway.
• Whether investors start valuing Outset more like a stabilizing med-tech platform than a distressed small-cap device name.

Bottom Line

Trigg's early-2026 OM sales were real, but they were modest and recurring rather than explosive. For investors, the more important question is whether management's margin-rebuild narrative keeps improving fast enough to outrun the overhang from steady insider selling.